Back
MELXE
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Metgasco Ltd - Ent To Shares In Byron Energy Limited
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in MELXE
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in MELXE
N/A
MELXE investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in MELXE also invest in...
Want more shares? Try these...
Memphasys Ltd. is a life sciences company. The company is headquartered in Homebush West, New South Wales. The company went IPO on 2007-05-14. The firm is engaged in developing novel medical devices, diagnostics, and media with applications to assisted reproduction technology (ART) in humans and animals. Its reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media. The firm's product pipeline includes Felix, ROSA, and AI-Port. The Felix is a patented, automated device for quickly separating high quality sperm from semen for use in human in vitro fertilization (IVF) procedures without causing damage to DNA. Felix has a sizable target market worldwide. The Company’s ROSA is an in vitro diagnostic that assesses semen and blood samples for the presence of oxidative stress. The AI-Port stores and transports animal semen for artificial insemination (AI) for up to four days without the harmful effects of freezing sperm used in standard AI procedures in livestock.
📊 Share price
